First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …

Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …

For several reasons, ovarian cancer is an excellent malignancy to consider the use of
'targeted'therapeutic strategies. However, to date, despite considerable effort, there remains …

Ovarian cancer continues to be a major cause of morbidity and mortality in women.
Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer …

For women with advanced ovarian cancer, rates of response to first-line chemotherapy are
high but most patients have relapses and become candidates for further chemotherapy …

The emergence of drug-resistant tumors during therapy for ovarian cancer remains an
obstacle to improving long-term outcomes. Active areas of ovarian cancer research include …

There is now a greater understanding of the molecular pathways in ovarian cancer, and
using this knowledge, a large number of new therapeutic agents can be tested. The success …

Ovarian cancer is the fifth largest cancer killer in women. Improved understanding of the
molecular pathways implicated in the pathogenesis of ovarian cancer has led to the …

Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the progression
of ovarian cancer through ascites formation and metastatic spread. Bevacizumab (Avastin® …

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …